2031년까지 글로벌 및 오만 암 치료제 시장 전망

Global & Oman Cancer Therapeutics Market to 2031

상품코드Norway Cancer Therapeutics Market.pdf
발행기관Business Market Insights
발행일2025.05.26
페이지 수100 Pages
포맷PDF
커버리지Country

₩3,600,000 – ₩6,600,000

보고서 요약(국문)

"오만의 암 발생률 2020" 연구에 따르면, 오만의 암 발생률은 남성 10만 명당 68.3명, 여성 10만 명당 79.4명으로 나타났습니다. 암 환자 수가 증가함에 따라 효과적인 치료법에 대한 수요도 늘어나고 있으며, 이는 암 치료제 시장의 성장을 견인하고 있습니다. 오만 보건부(MOH)는 특히 종양학 분야에서 의료 시스템 강화를 위해 적극적으로 노력해 왔습니다. 술탄 카부스 대학교 병원(SQUH)과 왕립 병원과 같은 주요 의료기관들은 필수적인 암 치료 서비스를 제공하고 있습니다. 또한, 정부 지원 시설인 술탄 카부스 종합 암 치료 및 연구 센터(SQCCCRC)가 2021년 7월 개원하여 고품질의 근거 기반 환자 중심 암 치료를 제공하고 있습니다. 이 센터는 최첨단 치료를 제공하는 동시에 암 치료 분야의 임상 및 과학적 발전을 지속적으로 촉진하는 데 전념하고 있습니다.

2023년 7월, 오만 보건부는 백금 기반 항암화학요법 후 질병이 진행된 전이성 소세포폐암(SCLC) 성인 환자에게 젭젤카(루르비넥테딘) 사용을 승인했습니다. 유통사인 이메디카는 앞서 2020년 파마마르와 전략적 파트너십을 체결하여 영국, 아일랜드, 북유럽 국가, 동유럽 일부 지역, 중동 및 북아프리카를 포함한 여러 지역에서 루르비넥테딘의 독점 유통 및 판매권을 확보했습니다.

보고서 요약(영어 원문)

According to the study "Cancer Incidence in Oman 2020," the crude cancer incidence rates were 68.3 per 100,000 men and 79.4 per 100,000 women in the country. As the number of cancer patients rises, there is an increasing demand for effective treatment options, driving growth in the cancer therapeutics market. Oman’s Ministry of Health (MOH) has been actively working to strengthen the healthcare system, particularly in oncology. Key institutions such as Sultan Qaboos University Hospital (SQUH) and the Royal Hospital provide essential cancer care services. Additionally, the Sultan Qaboos Comprehensive Cancer Care and Research Centre (SQCCCRC), a government-supported facility, opened in July 2021 to offer high-quality, evidence-based, patient-focused cancer treatment. The center is committed to delivering advanced care while fostering ongoing clinical and scientific advancements in cancer therapies.

In July 2023, the Ministry of Health in Oman approved Zepzelca (lurbinectedin) for use in adult patients with metastatic small cell lung cancer (SCLC) who have shown disease progression after platinum-based chemotherapy. Immedica, the distributor, had previously signed a strategic partnership with PharmaMar in 2020 for the exclusive distribution and commercialization of lurbinectedin across multiple regions including the UK, Ireland, Nordic countries, parts of Eastern Europe, and the Middle East and North Africa.

상세 목차

TABLE OF CONTENTS

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation:

4. Oman Cancer Therapeutics Market Landscape

4.1 Overview

4.2 Ecosystem Analysis

4.2.1 List of Vendors in the Value Chain

5. Cancer Therapeutics Market Key Market Dynamics

5.1 Cancer Therapeutics Market – Key Market Dynamics

5.2 Market Drivers

5.3 Market Restraints

5.4 Market Opportunities

5.5 Future Trends

5.6 Impact of Drivers and Restraints

6. Oman Cancer Therapeutics Market – Analysis

6.1 Oman Cancer Therapeutics Market Revenue (US$ Million), 2021–2031

6.2 Oman Cancer Therapeutics Market Revenue and Forecast Analysis

7. Oman Cancer Therapeutics Market Analysis – by Therapy Types

7.1 Oman Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types

8. Oman Cancer Therapeutics Market Analysis – by Indications

8.1 Oman Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications

9. Oman Cancer Therapeutics Market Analysis – by Distribution Channel

9.1 Oman Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel

10. Competitive Landscape

10.1 Heat Map Analysis by Key Players

10.1 Company Positioning and Concentration

11. Industry Landscape

11.1 Overview

11.2 Market Initiative

11.2 Partnerships and Collaborations

11.2 Other Developments

12. Company Profiles

12.1 Bristol-Myers Squibb Co

12.1. 1 Key Facts

12.1. 2 Business Description

12.1. 3 Products and Services

12.1. 4 Financial Overview

12.1. 5 SWOT Analysis

12.1. 6 Key Developments

12.2 AbbVie Inc

12.2. 1 Key Facts

12.2. 2 Business Description

12.2. 3 Products and Services

12.2. 4 Financial Overview

12.2. 5 SWOT Analysis

12.2. 6 Key Developments

12.3 Johnson & Johnson

12.3. 1 Key Facts

12.3. 2 Business Description

12.3. 3 Products and Services

12.3. 4 Financial Overview

12.3. 5 SWOT Analysis

12.3. 6 Key Developments

12.4 F. Hoffmann-La Roche Ltd

12.4. 1 Key Facts

12.4. 2 Business Description

12.4. 3 Products and Services

12.4. 4 Financial Overview

12.4. 5 SWOT Analysis

12.4. 6 Key Developments

12.5 Pfizer Inc

12.5. 1 Key Facts

12.5. 2 Business Description

12.5. 3 Products and Services

12.5. 4 Financial Overview

12.5. 5 SWOT Analysis

12.5. 6 Key Developments

12.6 AstraZeneca Plc

12.6. 1 Key Facts

12.6. 2 Business Description

12.6. 3 Products and Services

12.6. 4 Financial Overview

12.6. 5 SWOT Analysis

12.6. 6 Key Developments

12.7 Merck KGaA

12.7. 1 Key Facts

12.7. 2 Business Description

12.7. 3 Products and Services

12.7. 4 Financial Overview

12.7. 5 SWOT Analysis

12.7. 6 Key Developments

12.8 Novartis AG

12.8. 1 Key Facts

12.8. 2 Business Description

12.8. 3 Products and Services

12.8. 4 Financial Overview

12.8. 5 SWOT Analysis

12.8. 6 Key Developments

12.9 Astellas Pharma Inc

12.9. 1 Key Facts

12.9. 2 Business Description

12.9. 3 Products and Services

12.9. 4 Financial Overview

12.9. 5 SWOT Analysis

12.9. 6 Key Developments

12.10 Eli Lilly and Co

12.10. 1 Key Facts

12.10. 2 Business Description

12.10. 3 Products and Services

12.10. 4 Financial Overview

12.10. 5 SWOT Analysis

12.10. 6 Key Developments

13. Appendix

13.1 About Business Market Insights

13.2 List of Abbreviations

언급된 주요 기업들

TABLE OF COMPANIES

1. Bristol-Myers Squibb Co

2. AbbVie Inc

3. Johnson & Johnson

4. F. Hoffmann-La Roche Ltd

5. Pfizer Inc

6. AstraZeneca Plc

7. Merck KGaA

8. Novartis AG

9. Astellas Pharma Inc

10. Eli Lilly and Co

표 목록 (Tables)

TABLE OF TABLES

Table 1. Oman Cancer Therapeutics Market Segmentation

Table 2. List of Vendors

Table 3. Oman Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million)

Table 4. Oman Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million)

Table 5. Oman Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Therapy Types

Table 6. Oman Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Therapy Types

Table 7. Oman Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Indications

Table 8. Oman Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Indications

Table 9. Oman Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel

Table 10. Oman Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel

Table 11. List of Abbreviations

그림 목록 (Figures)

TABLE OF FIGURES

Figure 1. Impact Analysis of Drivers and Restraints

Figure 2. Oman Cancer Therapeutics Market Revenue, (US$ Million), 2021–2031

Figure 3. Heat Map Analysis by Key Players

Figure 4. Company Positioning and Concentration